Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Cyclophosphamide 3Zoledronic Acid 2Vincristine 2Tranexamic Acid 2Temozolomide 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ibandronic Acid 2Etoposide 2Doxorubicin 2samarium Sm-153 lexidronam 1robatumumab 1pegfilgrastim 1eltrombopag 1delta 24-sterol reductase 1Sodium Pertechnetate Tc 99m 1Sodium Chloride 1Samarium 1Radiation 1Pregabalin 1Plicamycin 1Neutrons 1Ifosfamide 1Histocompatibility Testing 1Guanabenz 1Gemcitabine 1Fluoridation 1Fibrin Tissue Adhesive 1Etanercept 1Diathermy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bone Neoplasms × robatumumab × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡